Tempest hits funding block for Phase III liver cancer drug-in-waiting
Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.
Therapy Area
Rallybio drops drug for rare maternal disorder following Phase II fail
AAN 2025: J&J reveals data for nipocalimab, showing long-term disease control in MG
Ten million new cases of HIV projected amid global reduction in funding
Sonnet BioTherapeutics reports positive results from ovarian cancer therapy trial
AD/PD 2025: Spotlight on ARIA as new data and evidence emerges for Alzheimer’s DMT use
Lundbeck’s superagonist prompts 61.2% seizure reduction
AC Immune reports interim outcomes from trial of Parkinson’s therapy
